SCHEDULE: State Street Discloses 5.3% Stake in Travere Therapeutics

State Street Corporation has reported a 5.3% beneficial ownership stake in Travere Therapeutics Inc. common stock as of December 31, 2025.

Summary

• State Street Corporation beneficially owns 4,756,666 shares of Travere Therapeutics Inc. common stock.
• This ownership represents 5.3% of the total class of securities.
• State Street Corporation, acting as a parent holding company, holds these shares through various investment adviser subsidiaries, including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd.
• The shares were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of Travere Therapeutics Inc.
• State Street Corporation exercises shared voting power over 4,485,757 shares and shared dispositive power over all 4,756,666 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it confirms a significant, passive institutional investment in Travere Therapeutics, which can lend stability and credibility to the stock.

Positives

• A significant institutional investor, State Street Corporation, holds a substantial stake (5.3%) in Travere Therapeutics, which can be viewed as a vote of confidence in the company's long-term prospects.
• The filing indicates the shares are held in the ordinary course of business, suggesting a passive investment rather than an activist stance that could introduce uncertainty.

Management Comments

• To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

StockSavvy.ai notes that institutional ownership by major asset managers like State Street Corporation is a common feature in the public markets. Such filings provide transparency into significant holdings, often reflecting passive investment strategies within broad market or sector-specific funds. For Travere Therapeutics, a biotechnology company, a stable institutional base can be a positive signal, indicating inclusion in major indices or investment portfolios.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder like State Street Corporation may provide a sense of stability and institutional confidence, potentially attracting other investors.
• Management: Confirms that a major institutional investor is holding a significant stake, but without an intent to influence control, allowing management to focus on long-term strategy.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of beneficial ownership by a large institutional investor. It does not contain new operational or financial information about Travere Therapeutics Inc. that would warrant a change in investment recommendation. The 5.3% stake by State Street Corporation is a passive investment, indicating inclusion in their managed funds rather than a strategic move to influence the company. Therefore, a 'hold' recommendation is appropriate, as the filing itself does not provide a basis for a 'buy' or 'sell' decision, but rather confirms existing institutional interest.

Keywords

Travere Therapeutics, State Street Corporation, Common Stock, Institutional Ownership, SEC Filing, Schedule 13G, Beneficial Ownership, TRVR